CCL

Összesen 7 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM065233
Első szerző:Canestraro, Martina
Cím:Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders / Martina Canestraro, Sara Galimberti, Hakan Savli, Giuseppe Alberto Palumbo, Daniele Tibullo, Balint Nagy, Francesca Guerrini, Simona Piaggi, Naci Cine, Maria Rita Metelli, Mario Petrini
Dátum:2010
ISSN:0165-4608
Megjegyzések:Both arsenic trioxide (ATO) and bortezomib show separate antileukemic activity. With the purpose of evaluating whether the combination of ATO and bortezomib would be an option for patients with acute leukemia, we incubated HL60 leukemic cells with ATO alone and in combination with bortezomib. ATO and bortezomib cooperated to induce cell death and to inhibit proliferation and apoptosis in a synergistic way. The combined treatment resulted in a stronger activation of caspase 8 and 9, moderate activation of caspase 3, and increased expression of Fas and tumor necrosis factor?related apoptosis-inducing ligand (TRAIL)-DR5 receptors. When bortezomib was added, some proapoptotic genes (CARD9, TRAIL) were upregulated, and some antiapoptotic genes (BCL2, BCL3, FLICE) were downregulated. When coincubated, approximately 80% of cells showed altered mitochondrial membrane permeability. Moreover, ATO alone and in combination with bortezomib abrogated DNA-binding activity of nuclear factor kappa beta (NF-?B). Gene expression assays showed that more deregulated genes were related to proliferation of leukocytes, tumorigenesis, control of cell cycle, hypoxia and oxidative stress, cytokines, PI3K-AKT, ERK-MAPK, EGF pathways, and ubiquitination. Finally, in three cases of acute myeloid leukemia, the addition of bortezomib to ATO significantly increased cytotoxicity. We conclude that the combination of bortezomib and ATO may be efficacious in the treatment of myeloid disorders.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
bortezomib
synergestic
antiproliferative
Megjelenés:Cancer Genetics And Cytogenetics 199 : 2 (2010), p. 110-120. -
További szerzők:Galimberti, Sara Savlı, Hakan Palumbo, Giuseppe Alberto Tibullo, Daniele Nagy Bálint (1956-) (molekuláris genetikus) Guerrini, Francesca Piaggi, Simona Cine, Naci Metelli, Maria Rita Petrini, Mario
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM073620
Első szerző:Galimberti, Sara
Cím:Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma / Galimberti S., Nagy B., Palumbo G. A., Ciancia E., Buda G., Orciuolo E., Melosi A., Lambelet P., Ronca F., Petrini M.
Dátum:2010
ISSN:0001-5792
Megjegyzések:In this study, we determined the allele and genotype frequencies of vascular endothelial growth factor (VEGF) G+405C, C-460T, C+936T and C-2578A single nucleotide polymorphisms (SNPs) in 32 patients affected by mantle cell lymphoma (MCL) and 58 healthy controls. Real-time PCR combined with melting curve analysis was used for the determination of SNP alleles. A significant difference in the allele frequency of VEGFC-460T and C+936T SNPs in MCL and healthy cases was not observed. On the contrary, VEGF G+405C and C-2578A SNP allele distribution was significantly lower in the patient group than among normal controls (p = 0.014, p = 0.001). This observation suggests that further investigation is warranted, both in vitro and in a larger series of patients, to further examine the role of VEGF polymorphisms in the pathogenesis of MCL. In addition, the use of quantitative real-time PCR combined with a melting curve analysis method in the detection of the 4 VEGF SNPs may have the potential to replace older and more time-consuming PCR-RFLP methods and bears further investigation.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
VEGF
Mantle cell lymphoma
Megjelenés:Acta Haematologica 123 : 2 (2010), p. 91-95. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Palumbo, Giuseppe Alberto Ciancia, Eugenio Buda, G. Orciuolo, E. Melosi, A. Lambelet, P. Ronca, F. Petrini, Mario
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM065229
035-os BibID:(PMID)21115902
Első szerző:Galimberti, Sara
Cím:ITF2357 Interferes with Apoptosis and Inflammatory Pathways in the HL-60 Model : a Gene Expression Study / Sara Galimberti, Martina Canestraro, Hakan Savli, Giuseppe Alberto Palumbo, Daniele Tibullo, Balint Nagy, Simona Piaggi, Francesca Guerrini, Naci Cine, Maria Rita Metelli, Mario Petrini
Dátum:2010
ISSN:0250-7005
Megjegyzések:Background: Cytotoxic and pro-apoptotic effectsexerted by the histone deacetylase inhibitor ITF2357 havebeen reported in acute myeloid leukemia HL-60 cells. In thecurrent study, its mechanism of action was investigated at themolecular level. Materials and Methods: Cell proliferationwas evaluated by methyl thiazol tetrazolium bromidereduction; apoptosis by annexin V, mitochondrialtransmembrane potential by tetramethylrhodamine ethylester. Functional experiments and gene expressionevaluations were performed by flow cytometry, microarray,and quantitative polymerase chain reaction. Results:Significant cell growth inhibition and increased apoptosiswere observed. ITF2357 reduced protein levels of BCL-2,MCL-1, and BCL-X, and increased levels of BAK. Exposureto ITF2357 did not abrogate NF-?B DNA binding. Aftermicroarray analysis, interleukin-10, interleukin-6, epidermalgrowth factor, peroxisome proliferator-activated receptor(PPAR), transforming growth factor ?, P38 mitogenactivatedprotein kinase, aryl hydrocarbon receptor,xenobiotic metabolism, PPAR/retinoic acid receptor, NF-?B,apoptosis, lipopolysaccharide/interleukin-1, G-proteinreceptor, T-cell receptor, and platelet-derived growth factorwere the de-regulated pathways. Conclusion: This studyshows that ITF2357 influences both proliferation andinflammatory pathways in HL-60 cells; this observationcould have possible applications in clinical practice.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
gene expression
pathways
apoptosis
Inflammatory
Megjelenés:Anticancer Research. - 30 (2010), p. 4025-4035. -
További szerzők:Canestraro, Martina Savlı, Hakan Palumbo, Giuseppe Alberto Tibullo, Daniele Nagy Bálint (1956-) (molekuláris genetikus) Piaggi, Simona Guerrini, Francesca Cine, Naci Metelli, Maria Rita Petrini, Mario
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM065230
Első szerző:Galimberti, Sara
Cím:Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms / Sara Galimberti, Balint Nagy, Eugenio Ciancia, Francesco Caracciolo, Edoardo Benedetti, Matteo Pelosini, Daniele Focosi, Mario Petrini
Dátum:2010
ISSN:1042-8194
Megjegyzések:Notwithstanding the most recent and effectivetherapeutic strategies, in the majority of patientsmantle cell lymphoma (MCL) is still aggressive, withmedian overall survival (OS) ranging from 26 to 57months, when patients are stratified according to themantle cell lymphoma international prognostic index(MIPI) [1,2]. Thus, several immunochemotherapycombinations have been explored to improve outcome,such as R-Hyper-CVAD (rituximab plushyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, methotrexate, cytarabine)[2], R-CHOP (rituximab plus cyclophosphamide,doxorubicin, vincristine, prednisone) [3],maxi-CHOP [4], bortezomib plus R-CHOP [5],and mTOR (mammalian target of rapamycin)inhibitors [6]. Moreover, also autologous transplantstill remains a valid therapeutic option for youngpatients responsive to dose-intensified inductionchemotherapy, with 6-year overall survival andprogression-free survival of 70% and 66%, respectively[7].
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
mantle cell lymphoma
VEGF
Polymorphism
Megjelenés:Leukemia & Lymphoma 52 : 1 (2010), p. 142-144. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Ciancia, Eugenio Caracciolo, Francesco Benedetti, Edoardo Pelosini, Matteo Focosi, Daniele Petrini, Mario
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM065423
Első szerző:Galimberti, Sara
Cím:Evaluation of the MDR1, ABCG2, Topoisomerases IIα and GST[pi] gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen / Sara Galimberti, Balint Nagy, Edoardo Benedetti, Simone Pacini, Stefania Brizzi, Francesco Caracciolo, Federico Papineschi, Elena Ciabatti, Francesca Guerrini, Rita Fazzi, Martina Canestraro, Mario Petrini
Dátum:2009
ISSN:1042-8194
Megjegyzések:The genomic profile of mantle cell lymphoma (MCL) has been reported to be significantly different from that of otherindolent lymphoproliferative disorders, Topoisomerase IIa, glutathione-s-transferasep (GSTp) and ABCG2 (BCRP)chemoresistance genes being over-expressed in MCL. In our study, expression levels of the above mentioned genes plusMDR1 were tested on bone marrow samples from 20 patients treated with Rituximab plus hyper-CVAD regimen, in order toevaluate a possible impact of the chemoresistance phenomenon on this promising treatment regimen. All patients expressedABCG2 and MDR1 genes; 85% of cases expressed GSTp and topoisomerase IIa. Only ABCG2 were over-expressed incomparison both with marrow from healthy donors and tonsilar CD5?/CD20? lymphocytes (adopted as normal counterpart of the neoplastic population). The overall response rate of the entire series was 87.5%, with 44% of complete responses.Fifty-seven percent of patients achieved the clearance of minimal residual disease. Levels of tested genes did not condition either quality of clinical response or PFS (76% at 24 months). Nevertheless, an ABCG2 higher expression appeared associated with a worse PFS and levels of this gene paralleled the status of minimal residual disease. A further evaluation ofABCG2 expression in larger series of MCL patients would be suitable.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
MDR1
ABCG2
topoisomerases
mantle
cell
lymphoma
Megjelenés:Leukemia & Lymphoma. - 48 : 8 (2009), p. 1502-1509. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Benedetti, Edoardo Pacini, Simone Brizzi, Stefania Caracciolo, Francesco Papineschi, Federico Ciabatti, Elena Guerrini, Francesca Fazzi, Rita Canestraro, Martina Petrini, Mario
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM065302
Első szerző:Nagy Bálint (molekuláris genetikus)
Cím:RAF-1 over-expression does condition survival of patients affected by aggressive mantle cell lymphoma / Nagy Bálint, Galimberti Sara, Benedetti Edoardo, Caracciolo Francesco, Pacini Simone, Vilpo Juhani, Ferrer Anna, Elonen Erkki, Franssila Kaarle, Knuutila Sakari, Petrini Mario
Dátum:2007
ISSN:0145-2126
Megjegyzések:Our results show over-expression of RAF-1 in MCL versus tonsilar B-cell population. The absence of significance versus normal bone marrows could be related to variability of neoplastic infiltration and, perhaps, to the microenvironment, that in MCL would be particularly relevant [11].The observation of a clinical prognostic significance of RAF-1 would be useful in the stratification of cases on the basis of a "biological risk".This would be particularly relevant in the context of the R-Hyper-CVAD regimen that, notwithstanding its high clinical efficacy (even in the eradicating minimal residual disease) has a not negligible toxicity (in our series, 30% of infective complications, with two patients who died because of sepsis).Consequently, if the prognostic role of RAF-1 over-expression will be confirmed in larger series of patients, different therapeutic strategies would be adopted in the treatment of MCL.In this line, Sorafenib, an oral multi-kinase inhibitor that targets also RAF kinases would be an interesting compound [12] for treatment of mantle cell lymphoma.
Tárgyszavak:Orvostudományok Klinikai orvostudományok levél
RAF-1
overexpression
mantle cell lymphoma
Megjelenés:Leukemia Research. - 31 : 11 (2007), p. 1595-1597. -
További szerzők:Galimberti, Sara Benedetti, Edoardo Caracciolo, Francesco Pacini, Simone Vilpo, Juhani Ferrer, Anna Elonen, Erkki Franssila, Kaarle Knuutila, Sakari Petrini, Mario
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM074834
Első szerző:Savlı, Hakan
Cím:Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39) : a Gene Expression Study / Hakan Savlı, Sara Galimberti, Deniz Sünnetçi, Martina Canestraro, Giuseppe Palumbo, Balint Nagy, Francesco Di Raimondo, Mario Petrini
Dátum:2015
ISSN:1300-7777
Megjegyzések:NTRODUCTION:We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39.METHODS:Oligonucleotide microarray platforms were used for gene expression and pathway analysis. Confirmation studies were performed using quantitative real time PCR.RESULTS:Bortezomib treatment has shown upregulated DIABLO and NF-?BIB (a NF-?B inhibitor) and downregulated NF-?B1, NF-?B2, and BIRC1 gene expressions. Combination treatment of the two compounds showed gene expression deregulations in concordance by the results of single bortezomib treatment. Especially, P53 was a pathway more significantly modified and a gene network centralized around the beta estradiol gene. Beta estradiol, BRCA2, and FOXA1 genes were remarkable deregulations in our findings.DISCUSSION AND CONCLUSION:Results support the suggestions about possible use of proteasome inhibitors in the treatment of high-risk myelodysplastic syndrome (MDS). NF-?B was observed as an important modulator in leukemic transformation of MDS.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
bortezomib
gene expression
myelodyplastic
Megjelenés:Turkish Journal of Hematology. - 32 : 3 (2015), p. 206-212. -
További szerzők:Galimberti, Sara Sünnetçi, Deniz Canesastraro, Martina Palumbo, Giuseppe Alberto Nagy Bálint (1956-) (molekuláris genetikus) Raimondo, Francesco Di Petrini, Mario
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1